NCT01524406View on ClinicalTrials.gov

Safety Study of HPP593 in Subjects During and After Limb Immobilization

PHASE1TerminatedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

June 30, 2013

Study Completion Date

June 30, 2013

Conditions
Muscle AtrophyHypodynamia
Interventions
DRUG

HPP593

Oral, twice a day.

DRUG

Placebo

Oral, twice a day.

Trial Locations (1)

63110

Washington University School of Medicine Division of Geriatrics and Nutritional Studies, St Louis

Sponsors
All Listed Sponsors
lead

High Point Pharmaceuticals, LLC.

INDUSTRY